Home » Stocks » Taysha Gene Therapies

Taysha Gene Therapies, Inc. (TSHA)

Stock Price: $20.02 USD -0.53 (-2.58%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 716.96M
Revenue (ttm) n/a
Net Income (ttm) -27.77M
Shares Out 34.52M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $20.02
Previous Close $20.55
Change ($) -0.53
Change (%) -2.58%
Day's Open 20.70
Day's Range 19.95 - 20.83
Day's Volume 61,307
52-Week Range 18.16 - 27.53

More Stats

Market Cap 716.96M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 34.52M
Float 5.76M
EPS (basic) n/a
EPS (diluted) -0.80
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 255,270
Short Ratio 0.27
Short % of Float 4.43%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -27.77M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$34.75*
(73.58% upside)
Low
29.0
Current: $20.02
High
45.0
Target: 34.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Taysha Gene Therapies, Inc.
Country United States
Employees 10
CEO R. A. Session

Stock Information

Ticker Symbol TSHA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TSHA
IPO Date September 24, 2020

Description

Taysha Gene Therapies, a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.